Background
Higher rates of adverse cardiac events have been observed in patients with small vessel disease. In a pooled analysis of the SPIRIT III and IV trials, we compared an everolimus-eluting stent (EES) to a paclitaxel-eluting stent (PES) for treatment of small (<2.5 mm) and larger vessels (≥2.5 mm). At 1 year, absolute reduction in TLR and composite safety and efficacy measures were particularly marked for EES vs. PES in small vessels. Here we report outcomes through 2 years.
Methods
In SPIRIT III ( n =1001) and SPIRIT IV ( n =3687), a total of 4688 patients were randomized 2:1, EES vs. PES, and data were pooled for a patient-level analysis. Inclusion and exclusion criteria were comparable with similar baseline characteristics and event definitions. EES vs. PES performance in small ( n =1019) and larger vessels ( n =2586) was evaluated at 2 years.
Methods
In SPIRIT III ( n =1001) and SPIRIT IV ( n =3687), a total of 4688 patients were randomized 2:1, EES vs. PES, and data were pooled for a patient-level analysis. Inclusion and exclusion criteria were comparable with similar baseline characteristics and event definitions. EES vs. PES performance in small ( n =1019) and larger vessels ( n =2586) was evaluated at 2 years.
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
